Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.

Authors

Shadi Chamseddine
Yehia I Mohamed
Sunyoung S Lee
James C Yao
Zishuo Ian Hu
Hop S Tran Cao
Lianchun Xiao
Ryan Sun
Jeffrey S Morris
Rikita I Hatia
Manal Hassan
Dan G Duda
Maria Diab
Amr Mohamed
Ahmed Nassar
Saumil Datar
Hesham M Amin
Ahmed Omar Kaseb

Publication Date

8-23-2023

Journal

Oncology

Abstract

INTRODUCTION: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients.

METHODS: We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method.

RESULTS: The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18.

CONCLUSION: Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC.

Keywords

Interleukins, Biomarker, Hepatocellular carcinoma, Overall survival, Prognosis

Comments

PMID: 37467732